MX2009003764A - Preparaciones de celulas presentadoras de antigeno artificiales y su uso en terapias celulares. - Google Patents
Preparaciones de celulas presentadoras de antigeno artificiales y su uso en terapias celulares.Info
- Publication number
- MX2009003764A MX2009003764A MX2009003764A MX2009003764A MX2009003764A MX 2009003764 A MX2009003764 A MX 2009003764A MX 2009003764 A MX2009003764 A MX 2009003764A MX 2009003764 A MX2009003764 A MX 2009003764A MX 2009003764 A MX2009003764 A MX 2009003764A
- Authority
- MX
- Mexico
- Prior art keywords
- presenting cells
- antigen presenting
- artificial antigen
- preparation
- inactivated
- Prior art date
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title abstract 3
- 238000002659 cell therapy Methods 0.000 title abstract 2
- DWAOUXYZOSPAOH-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]furo[3,2-g]chromen-7-one;hydrochloride Chemical compound [Cl-].O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC[NH+](CC)CC DWAOUXYZOSPAOH-UHFFFAOYSA-N 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen métodos de procesamiento de células presentadoras de antígeno artificiales inactivadas (aAPCs) y células presentadoras de antígeno artificiales con especificad para péptidos antigénicos seleccionados, incluyendo su generación y uso en composiciones de terapia celular que comprenden linfocitos T citotóxicos activados; las aAPCs inactivadas son ventajosamente generadas a través de entrecruzamiento, tal como mediante una fotoreacción que involucra un derivado de psoralen e irradiación de UVA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84929906P | 2006-10-04 | 2006-10-04 | |
PCT/US2007/021326 WO2008045286A2 (en) | 2006-10-04 | 2007-10-04 | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009003764A true MX2009003764A (es) | 2009-04-22 |
Family
ID=39283361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009003764A MX2009003764A (es) | 2006-10-04 | 2007-10-04 | Preparaciones de celulas presentadoras de antigeno artificiales y su uso en terapias celulares. |
Country Status (13)
Country | Link |
---|---|
US (2) | US8124408B2 (es) |
EP (1) | EP2079830B1 (es) |
JP (1) | JP5543207B2 (es) |
KR (1) | KR20090060450A (es) |
CN (1) | CN101548008B (es) |
AU (1) | AU2007307206B2 (es) |
BR (1) | BRPI0720342A2 (es) |
CA (1) | CA2665568C (es) |
ES (1) | ES2603418T3 (es) |
IL (2) | IL197845A (es) |
MX (1) | MX2009003764A (es) |
NZ (1) | NZ575571A (es) |
WO (1) | WO2008045286A2 (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ569541A (en) * | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
US20100041133A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20100040546A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20100042072A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20120034157A1 (en) * | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
EP2221060A1 (en) | 2009-02-05 | 2010-08-25 | Universitätsklinikum Heidelberg | Use of specific peptides in the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM) |
WO2010099205A1 (en) * | 2009-02-24 | 2010-09-02 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (pml) |
JP2011004705A (ja) * | 2009-06-29 | 2011-01-13 | Olympus Corp | 細胞分離装置および細胞分離方法 |
WO2011020047A1 (en) | 2009-08-14 | 2011-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
KR101224466B1 (ko) * | 2010-05-20 | 2013-01-22 | 가톨릭대학교 산학협력단 | 토포아이소머라아제 2 알파 유래의 종양항원 단백질, 유전자, 또는 펩타이드 |
CN102634485A (zh) * | 2012-03-15 | 2012-08-15 | 上海市浦东新区公利医院 | 一种表达il-17的胶质瘤细胞株 |
EP3567102A1 (en) | 2012-04-24 | 2019-11-13 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
CN102718869B (zh) * | 2012-06-06 | 2014-08-06 | 西安交通大学 | 一种固定化呈递免疫共刺激分子的微球及其制备方法 |
AU2014216355A1 (en) | 2013-02-12 | 2015-09-03 | Texas Tech University System | Composition and method for diagnosis and immunotherapy of lung cancer |
EP2958170A4 (en) * | 2013-02-13 | 2016-08-17 | Toray Battery Separator Film | SEPARATOR FOR BATTERIES AND METHOD FOR MANUFACTURING SEPARATOR FOR BATTERIES |
WO2014165866A2 (en) * | 2013-04-01 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for immune-based diagnosis, prevention and personalized treatment of narcolepsy |
CN103254313B (zh) * | 2013-04-08 | 2015-07-01 | 中国人民解放军第三军医大学 | 组合的ctl抗原表位及其应用 |
CN112795594A (zh) | 2013-05-14 | 2021-05-14 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
JP6352912B2 (ja) * | 2013-06-21 | 2018-07-04 | 国立大学法人 岡山大学 | 異常活性化細胞検出による悪性腫瘍の検査方法および異常活性化細胞除去環流返血治療装置 |
EP3995145A1 (en) * | 2013-06-24 | 2022-05-11 | NexImmune, Inc. | Compositions and methods for immunotherapy |
WO2015061694A2 (en) | 2013-10-25 | 2015-04-30 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta t cells for immunotherapy |
CA2938887C (en) | 2014-02-14 | 2023-04-11 | Laurence J. N. Cooper | Chimeric antigen receptors and methods of making |
EP3134437A1 (en) | 2014-04-23 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
CA2945393C (en) | 2014-04-24 | 2021-03-23 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
EP3145516A4 (en) * | 2014-05-20 | 2018-06-13 | Kiromic, LLC | Methods and compositions for treating malignancies with dendritic cells |
US10570186B2 (en) | 2014-11-05 | 2020-02-25 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (CAR) to selectively target protein complexes |
JP2017535284A (ja) | 2014-11-05 | 2017-11-30 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 |
CN116869964A (zh) | 2014-12-24 | 2023-10-13 | 耐克西缪恩有限公司 | 用于免疫疗法的纳米颗粒组合物和方法 |
GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
CN108472314A (zh) | 2015-07-31 | 2018-08-31 | 明尼苏达大学董事会 | 修饰的细胞和治疗方法 |
KR101769025B1 (ko) * | 2015-08-04 | 2017-08-17 | 전남대학교산학협력단 | 브랜치드 멀티펩티드 조성물 및 이를 포함하는 백신 |
US11059879B2 (en) | 2015-10-27 | 2021-07-13 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
AU2017279548A1 (en) | 2016-06-08 | 2018-12-13 | Precigen, Inc. | Cd33 specific chimeric antigen receptors |
KR102553195B1 (ko) | 2016-07-29 | 2023-07-07 | 주노 쎄러퓨티크스 인코퍼레이티드 | 항-cd19 항체에 대한 항-이디오타입 항체 |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
WO2018101796A1 (ko) * | 2016-12-02 | 2018-06-07 | 가톨릭대학교 산학협력단 | 멀티플렉스 CRISPR-Cas9 시스템을 이용한 HLA 결핍 세포주로부터 제조된 인공항원제시세포 및 이의 용도 |
CN108264550B (zh) * | 2017-01-04 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种识别源自于prame抗原短肽的tcr |
CN110462040A (zh) | 2017-01-10 | 2019-11-15 | 英特拉克森公司 | 通过新基因开关表达系统调节多肽的表达 |
CN110997920A (zh) | 2017-06-07 | 2020-04-10 | 英特拉克森公司 | 新型细胞标签的表达 |
EP3655027A4 (en) * | 2017-07-21 | 2021-04-21 | Berkeley Lights, Inc. | SYNTHETIC ANTIGEN PRESENTATION SURFACES, COVALENTLY FUNCTIONALIZED SURFACES, ACTIVATED T-LYMPHOCYTES AND THEIR USES |
CN109337872B (zh) * | 2017-07-27 | 2023-06-23 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
CN109575120B (zh) * | 2017-09-28 | 2022-10-28 | 香雪生命科学技术(广东)有限公司 | 识别prame抗原短肽的tcr及其编码序列 |
MX2020006881A (es) * | 2017-12-29 | 2020-10-01 | Cerus Corp | Sistemas y metodos para tratar fluidos biologicos. |
WO2019139972A1 (en) | 2018-01-09 | 2019-07-18 | Board Of Regents, The University Of Texas System | T cell receptors for immunotherapy |
WO2020048990A1 (en) | 2018-09-04 | 2020-03-12 | Treos Bio Zrt | Peptide vaccines |
FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
BR112021010297A2 (pt) | 2018-11-28 | 2021-08-24 | Board Of Regents, The University Of Texas System | Edição de genomas multiplexadores de células imunes para aumentar a funcionalidade e resistência ao ambiente supressivo |
MX2021006393A (es) | 2018-11-29 | 2021-10-13 | Univ Texas | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. |
EP4055150A4 (en) | 2019-11-06 | 2023-12-06 | Baylor College Of Medicine | METHOD FOR PRODUCING CYTOTOXIC EFFECTOR MEMORY T CELLS FOR T CELL TREATMENT OF CANCER |
WO2021163191A1 (en) | 2020-02-10 | 2021-08-19 | Board Of Regents, The University Of Texas System | Methods for rapid cloning and expression of hla class i cells |
CN111333711B (zh) * | 2020-03-18 | 2020-10-09 | 北京鼎成肽源生物技术有限公司 | 一种肺癌抗原组合及其应用、细胞毒性t淋巴细胞 |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
JP2023537558A (ja) | 2020-05-27 | 2023-09-04 | アンチオン バイオサイエンシーズ エスアー | 目的の抗原にcar t細胞をリダイレクトするためのアダプター分子 |
CN111879684B (zh) * | 2020-06-18 | 2021-12-21 | 山东大学 | 一种基于流式细胞术的吞噬细胞功能检测方法 |
CN114887091B (zh) * | 2021-03-17 | 2024-01-30 | 中国科学院江西稀土研究院 | 一种基于表面耦合诱导等离子体的冷链消毒装置及方法 |
TW202309071A (zh) | 2021-05-05 | 2023-03-01 | 德商英麥提克生物技術股份有限公司 | 特異性結合prame之抗原結合蛋白 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
EP0890363A3 (en) | 1989-10-26 | 1999-08-25 | ISAACS, Stephen T. | A device for nucleic acid sterilization |
US5583031A (en) | 1992-02-06 | 1996-12-10 | President And Fellows Of Harvard College | Empty major histocompatibility class II heterodimers |
US6204058B1 (en) | 1992-02-07 | 2001-03-20 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US6001365A (en) | 1992-02-19 | 1999-12-14 | The Scripps Research Institute | In vitro activation of cytotoxic T cells |
US5314813A (en) | 1992-02-19 | 1994-05-24 | Scripps Research Institute | Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines |
JPH08509606A (ja) | 1993-04-20 | 1996-10-15 | ロビンソン,ウィリアム エス. | 細胞内感染因子に感染した個体を処置する方法および物質 |
WO1995004817A1 (en) | 1993-08-06 | 1995-02-16 | Cytel Corporation | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl |
FR2709309B1 (fr) | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Compositions cellulaires, préparation et utilisations thérapeutiques. |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
FR2728584A1 (fr) | 1994-12-22 | 1996-06-28 | Centre Nat Rech Scient | Procede de transfert de gene dans des cellules activees a partir d'un etat de repos |
DE69628154T2 (de) | 1995-03-08 | 2004-03-18 | The Scripps Research Institute, La Jolla | Antigen präsentierendes system und aktivierung von t-zellen |
AU6267496A (en) | 1995-06-07 | 1996-12-30 | Steritech, Inc. | Methods of inactivating leukocytes and inhibiting cytokine p roduction in blood products |
US20030022820A1 (en) | 1995-12-14 | 2003-01-30 | Linda A. Sherman | In vivo activation of tumor-specific cytotoxic t cells |
US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
ATE347588T1 (de) | 1996-05-23 | 2006-12-15 | Scripps Research Inst | Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten |
PT937251E (pt) | 1996-09-06 | 2007-01-31 | Ortho Mcneil Pharm Inc | Purificação de células específicas de antigénio |
CA2278847A1 (en) | 1997-01-31 | 1998-08-06 | Hemosol Inc. | Method for the production of selected lymphocytes |
DE19740571C1 (de) * | 1997-09-15 | 1999-03-18 | Gsf Forschungszentrum Umwelt | Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität |
US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
GB9905911D0 (en) * | 1999-03-15 | 1999-05-05 | Photocure As | Method |
WO2000063690A1 (en) | 1999-04-16 | 2000-10-26 | Ortho-Mcneil Pharmaceutical, Inc. | Enriched antigen-specific t-cells, and related therapeutic and prophylactic compositions and methods |
US6105775A (en) | 1999-04-20 | 2000-08-22 | Pakon, Inc. | Sleeving system for photographic film negatives |
AU2001288863A1 (en) | 2000-09-15 | 2002-03-26 | Ortho-Mcneil Pharmaceutical, Inc. | Compositions and methods for inducing specific cytolytic t cell responses |
US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
ES2643582T3 (es) | 2001-02-20 | 2017-11-23 | Janssen Pharmaceuticals, Inc. | Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer |
FR2824567B1 (fr) * | 2001-05-11 | 2003-08-08 | Inst Nat Sante Rech Med | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene |
DE60233231D1 (de) | 2001-05-15 | 2009-09-17 | Ortho Mcneil Janssen Pharm | Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen |
DE60210623T2 (de) | 2001-05-30 | 2007-02-15 | Fondazione Téléthon | Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen |
US7718196B2 (en) | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
US8222033B2 (en) | 2002-08-12 | 2012-07-17 | Argos Therapeutics, Inc. | CD4+CD25− T cells and Tr1-like regulatory T cells |
AU2004224425B2 (en) * | 2003-02-06 | 2010-06-24 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
WO2005051975A2 (en) | 2003-07-03 | 2005-06-09 | Avatar Biotechnologies, Inc. | Methods for obtaining molecules with reduced immunogenicity |
ES2653570T3 (es) * | 2004-05-27 | 2018-02-07 | The Trustees Of The University Of Pennsylvania | Células presentadoras de antígeno artificiales novedosas y usos de las mismas |
-
2007
- 2007-10-04 CA CA2665568A patent/CA2665568C/en not_active Expired - Fee Related
- 2007-10-04 NZ NZ575571A patent/NZ575571A/en not_active IP Right Cessation
- 2007-10-04 ES ES07852532.6T patent/ES2603418T3/es active Active
- 2007-10-04 WO PCT/US2007/021326 patent/WO2008045286A2/en active Application Filing
- 2007-10-04 BR BRPI0720342-0A patent/BRPI0720342A2/pt not_active Application Discontinuation
- 2007-10-04 JP JP2009531452A patent/JP5543207B2/ja not_active Expired - Fee Related
- 2007-10-04 KR KR1020097008320A patent/KR20090060450A/ko not_active Application Discontinuation
- 2007-10-04 EP EP07852532.6A patent/EP2079830B1/en active Active
- 2007-10-04 MX MX2009003764A patent/MX2009003764A/es active IP Right Grant
- 2007-10-04 CN CN2007800445075A patent/CN101548008B/zh not_active Expired - Fee Related
- 2007-10-04 AU AU2007307206A patent/AU2007307206B2/en not_active Ceased
- 2007-10-04 US US11/906,807 patent/US8124408B2/en not_active Expired - Fee Related
-
2009
- 2009-03-26 IL IL197845A patent/IL197845A/en active IP Right Grant
-
2012
- 2012-01-13 US US13/350,085 patent/US8357533B2/en active Active
- 2012-12-02 IL IL223376A patent/IL223376A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BRPI0720342A2 (pt) | 2018-09-18 |
NZ575571A (en) | 2011-11-25 |
EP2079830B1 (en) | 2016-08-17 |
WO2008045286A3 (en) | 2008-12-18 |
US8124408B2 (en) | 2012-02-28 |
IL197845A (en) | 2013-04-30 |
CN101548008A (zh) | 2009-09-30 |
JP2010505845A (ja) | 2010-02-25 |
US20120115223A1 (en) | 2012-05-10 |
CA2665568A1 (en) | 2008-04-17 |
US8357533B2 (en) | 2013-01-22 |
WO2008045286A2 (en) | 2008-04-17 |
EP2079830A2 (en) | 2009-07-22 |
IL223376A (en) | 2015-10-29 |
AU2007307206A1 (en) | 2008-04-17 |
ES2603418T3 (es) | 2017-02-27 |
AU2007307206B2 (en) | 2016-02-11 |
CA2665568C (en) | 2018-01-09 |
JP5543207B2 (ja) | 2014-07-09 |
IL197845A0 (en) | 2011-08-01 |
KR20090060450A (ko) | 2009-06-12 |
US20090017000A1 (en) | 2009-01-15 |
IL223376A0 (en) | 2013-02-03 |
CN101548008B (zh) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009003764A (es) | Preparaciones de celulas presentadoras de antigeno artificiales y su uso en terapias celulares. | |
BR112021024966A2 (pt) | Composições e métodos para administração subcutânea de imunoterapia de câncer | |
Bekeschus et al. | Potentiating anti-tumor immunity with physical plasma | |
Gameiro et al. | Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing | |
PH12019502661A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
AU2018200571B2 (en) | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules | |
NZ609460A (en) | Method for activating helper t cell | |
MX359234B (es) | Inmunoterapia de celulas t objetivadas en ciclina a1 para cancer. | |
MX2013012596A (es) | Nanoportadores sintéticos tolerogénicos para generar linfocitos t reguladores cd8+. | |
WO2008039874A3 (en) | Cancer stem cell antigen vaccines and methods | |
WO2008085562A3 (en) | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies | |
MX363307B (es) | Plataformas para suministro de antigenos. | |
MX2021006932A (es) | Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica. | |
MX2009008620A (es) | Un metodo para mejorar la respuesta de celulas t. | |
PL2327763T3 (pl) | Generowanie komórek T specyficznych względem antygenu | |
SI2102331T1 (sl) | Antitumorsko cepivo, izvedeno iz normalnih kemično modificiranih CD4+ celic | |
MX2019000022A (es) | Células veto generadas a partir de linfocitos t de memoria. | |
WO2008034074A3 (en) | Cyclosphosphamide in combination with anti-idiotypic vaccines | |
MX2022003195A (es) | Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga. | |
Judy et al. | Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery | |
CY1124082T1 (el) | Μεθοδοι θεραπειας με χρηση κινητοποιητων βλαστικων κυτταρων και ανοσοκατασταλτικων παραγοντων | |
MX2019009121A (es) | Antcuerpos anti-kaag1 o fragmento de union al antigeno del mismo para el tratamiento de cancer de mama triple negativo. | |
WO2009032256A3 (en) | Apc activators in combination with a cytokine-secreting cell and methods of use thereof | |
WO2010039924A3 (en) | Th1 vaccination priming for active immunotheraphy | |
WO2009072555A1 (ja) | 癌ワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |